Thursday, July 25th 2019 5:30 PM – 7:30 PM Broad Street Ministry (315 S. Broad Street) Join the effort to eliminate Hepatitis C in Philadelphia. In honor of World Hepatitis Day, Philadelphia FIGHT Community Health Centers welcomes you to enjoy light appetizers and refreshing mocktails, courtesy of Safran Turney Hospitality (Bud & Read more…
July 30th, 2019, 3:00pm ET Learn about Hepatitis B and the Opioid Epidemic, and about the importance of increasing efforts to address hepatitis B vaccination and awareness, in this AAPCHO webinar! Learn more and register here: https://zoom.us/webinar/register/WN_er1VukvFT8GOCfWqF913Eg Time duration: 1 hour and 15 minutes Background: Recent outbreaks of hepatitis B Read more…
View the April 30 press release from the FDA here. The U.S. Food and Drug Administration approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17. Mavyret was previously approved to treat HCV in adults in 2017. “Direct-acting Read more…
Although 124 countries now have national plans for viral hepatitis elimination, 42% of plans have no domestic funding. The United States lags behind in this estimation of the year countries will achieve the World Health Organization elimination target. From Infohep: Most countries will struggle to eliminate hepatitis C by 2030 Read more…
The state of Washington said Friday it has selected AbbVie to provide hepatitis C medication through an unconventional subscription payment program that seeks to expand patient access while containing drug costs. The contract is part of the state’s plan to eliminate the common viral infection by 2030. “Last year, I committed Washington to Read more…
Background Hepatitis C virus (HCV) testing in persons born from 1945 to 1965 has had limited adoption despite guidelines, particularly among racial/ethnic minorities and socioeconomically disadvantaged patients, who have a higher prevalence of disease burden. We examined the effectiveness of a multifaceted intervention to improve HCV screening in a large Read more…
Press release from the Louisiana Department of Health March 26, 2019 The Louisiana Department of Health and Department of Corrections announced today their selection of Asegua Therapeutics LLC (a subsidiary of Gilead Sciences, Inc.) as their hepatitis C subscription model pharmaceutical partner, to provide the State with unrestricted access to Read more…
The first prospective study of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection in patients with any type of cancer has not only demonstrated that the treatment is safe and efficacious in this population, but that attaining sustained virologic response (SVR) can confer eligibility to participate in chemotherapeutic trials. Read more…
Tuesday, March 5 2019 2:00 pm ET Register for Part 1 of the Learning Collaborative here! HepCAP co-chair Jack will be speaking on treatment policy changes and how the Philadelphia Department of Public Health is expanding resources for screening and treatment! Topics covered in Part 1: HCV Programming in Community Read more…
Click the link below to see a video of Priya Mammen, MD, MPH, discussing how Thomas Jefferson’s Emergency Out Out Program is saving and improving the lives of many Philadelphians through HIV screening. Click Here to Watch!